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ABSTRACT
Monoclonal gammopathy of undetermined significance (MGUS) and multiple 
myeloma (MM) are characterised by the accumulation of malignant plasma cells within 
bone marrow and lead to a range of abnormalities in the peripheral blood T cell 
repertoire. We investigated the level of inflammatory chemokines within the bone 
marrow and blood of patients with MGUS and MM and related this to the pattern of 
chemokine receptor expression on T cells in both compartments. 
The expression of a wide range of chemokine ligands for CXCR3 and CCR4 was 
markedly increased within the bone marrow of patients with MGUS and MM compared 
to healthy donors. The most marked effects were seen for CCL4 and CXCL9 which 
were increased by 4 and 6 fold respectively in the bone marrow of patients with 
myeloma. The expression of CXCR3 and CCR4, the major TH1 and TH2-associated 
chemokine receptors, was increased substantially on T cells within the bone marrow 
of patients whereas the percentage of CXCR3-expressing T cells within blood was 
correspondingly decreased. The presence of even small numbers of neoplastic plasma 
cells or associated stroma can therefore generate an inflammatory chemokine tumour 
microenvironment. This leads to the selective recruitment or retention of specific T cell 
subsets which is likely to underlie many of the features regarding the peripheral T cell 
repertoire in myeloma and may also contribute to the immune suppression associated 
with this disease. This local inflammatory reaction may represent a tumour-specific 
immune response or may itself play an important role in tumour progression and as 
such may offers a potential novel target for therapeutic intervention.
INTRODUCTION
Monoclonal gammopathy of undetermined 
significance (MGUS) and multiple myeloma (MM) are 
related disorders defined by the presence of neoplastic 
plasma cells within the bone marrow and monoclonal 
immunoglobulin within serum. MGUS is an asymptomatic 
premalignant form of myeloma with an approximately 
1% risk each year of progression to MM for an individual 
patient. Indeed, it is now believed that MGUS precedes the 
development of virtually every case of MM [1, 2]. 
Patients with MM exhibit a variety of numerical and 
functional T cell abnormalities, including increased numbers 
of memory cells, reduced clonal diversity and impaired 
functional and viral-specific responses [3]. A relative 
accumulation of T cells within the bone marrow has also 
been reported and is associated with the development of an 
oligoclonal TCR-Vβ repertoire [4–7]. These changes may 
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contribute to the relative immunodeficiency of MM but their 
aetiology and relevance to tumour progression is unknown. 
The role of regulatory T cells in the development of MM 
is also under debate and remains controversial [8–12]. 
TH17 cells are also of considerable interest in relation to 
tumour immunity and are increased in both the marrow and 
blood of patient with paraproteinaemia [13–23].  
T cells in the bone marrow of patients with 
paraproteinemia might potentially be involved in either 
the suppression or support of the tumour cell population. 
Indeed, TH17-associated pro-inflammatory
 cytokines have 
been shown to increase the survival of MM cells both 
in vitro and in vivo [10, 13, 24, 25] and may play a role in 
development of bone disease [13, 26]. 
The altered distribution of T cell subsets between 
the bone marrow and peripheral blood of patients 
with paraproteinaemia is likely to reflect the pattern 
of migration and retention of cells within marrow. 
Chemokine gradients are of central importance and 
there are data showing the importance of an upregulated 
CXCR4/CXCR7/CXCL12 axis in driving recruitment of 
tumour cells [27–28] into the bone marrow in patients 
with multiple myeloma. Other chemokines have been 
shown to be elevated in patients with multiple myeloma 
including CCL3 and CCL20 [29–30]. Increased levels 
of key cytokines have also been shown to progressively 
increase from controls to smouldering myeloma to 
multiple myeloma including CXCL8 (IL-8), IL-10, TNFα, 
IL6 and IFNγ [31] . A decrease in NK cell numbers in the 
bone marrow of patients with myeloma has been shown to 
correlate with a decrease in the chemokine CXCL12 and 
an upregulation of CXCR3 ligand expression [32].
We therefore measured chemokine levels within 
these compartments and related these findings to the 
distribution of chemokine receptor expression on CD4+ and 
CD8+ T cells.  Our findings reveal an inflammatory tumour 
microenvironment within the bone marrow in patients with 
paraproteinaemia that markedly alters the distribution of 
individual T cell subsets and leads to accumulation of T 
cells within the tumour microenvironment.
RESULTS
The expression of a wide range of inflammatory 
chemokines is increased in the bone marrow and 
blood of patients with paraproteinaemia 
In initial studies we focussed on the level of 
expression of a range of inflammatory chemokines that are 
ligands for the chemokine receptors CXCR3 and CCR4. 
These two receptors were chosen as their expression is 
relatively selective on TH1 and TH2 cells respectively. 
CXCR3 is expressed on virtually all TH1 cells and binds to 
three chemokine ligands CXCL9 (MIG), CXCL10 (IP-10) 
and CXCL11 (ITAC).  We used Luminex analysis to 
determine the pattern of expression of these ligands 
within marrow and blood samples from the study cohort 
(Figure  1A–1C). 
All three chemokines were expressed at low levels 
in the control group. However, it was noteworthy that 
CXCL9 and CXCL10 were undetectable within the bone 
marrow whereas low levels were observed within blood. 
This indicates that the expression of these inflammatory 
chemokines is normally under tight regulation within the 
marrow compartment. 
Interestingly, the expression of both CXCL9 and 
CXCL10 was markedly increased in the bone marrow 
of the patient groups, and appeared to increase in a 
progressive fashion during the clinical transition from 
MGUS to myeloma although a definitive longitudinal 
study would be needed to confirm this.  Of note was the 
observation that expression was higher within the bone 
marrow than the blood which lead to a reversal of the 
normal marrow:blood gradient of chemokine expression 
(Figure 1A and 1B). No major or consistent changes were 
observed in relation to expression of CXCL11 between 
MM or MGUS patients and the control group (Figure 1C).
We next went on to examine the expression level 
of chemokines which are major ligands for CCR4, a 
chemokine receptor found predominantly on TH2 cells. 
Luminex analysis was used to determine the levels of 
CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β) and 
CCL20 (MIP-3α) in serum samples from blood and bone 
marrow (Figure 2A–2D).  
Within healthy controls the concentration of 
all the chemokines was found to be low and broadly 
similar between the blood and marrow compartments. 
Specifically, CCL2 and CCL3 were undetectable in 
marrow with very low levels being found within blood. 
CCL4 was measurable at low level in both marrow and 
blood whereas CCL20 was found at slightly higher level 
within the marrow and was not detectable in blood.
Remarkably, the expression patterns of CCL2, 
CCL3, CCL4 and CCL20 were very similar in the patient 
groups and showed substantially higher levels in both the 
blood and bone marrow compared to the control group. 
This increase in expression was pronounced, with relative 
increases of between 2 and 20 fold in MM patients 
compared to the healthy controls. A particularly striking 
feature was that chemokine levels increased sequentially 
during the clinical progression from healthy donors 
through to MGUS and finally MM.
The C-X-C chemokines CXCL12 and CXCL8 
are also progressively increased in blood and BM 
in patients with MGUS and MM 
The expression of CXC chemokines such as 
CXCL12 (SDF-1) and CXCL8 (IL-8) has been reported to 
be modulated in patients with MM [31, 33–36]. CXCL12 
is the ligand for CXCR4 whereas CXCL8 binds to the 
CXCR1 and CXCR2 receptors. We therefore studied 
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the expression of these molecules in the blood and bone 
marrow within our study group (Figure 3A and 3B). Very 
marked changes were observed in the expression pattern 
between the control and patient groups. CXCL8 levels 
were very low in control group and only small amounts 
of CXCL12 were observed in the bone marrow of healthy 
subjects. In contrast, the expression of both molecules 
was increased in the patient group with the highest levels 
being observed in with the bone marrow of patients with 
myeloma (Figure 3A and 3B).
The pattern of distribution of CXCR3+ T cells 
between blood and bone marrow is altered in 
patients with multiple myeloma
In view of the clear alteration in the pattern of 
distribution of the chemokine ligands for CXCR3 and 
CCR4 within our patient groups, we then went on to study 
the expression of these chemokine receptors on T cells in 
blood and bone marrow. Unfortunately it was not possible 
to analyse T cells within bone marrow samples from 
patients with MGUS due to lack of clinical samples.
CXCR3 expression is strongly correlated with a 
functional TH1 phenotype and in healthy control subjects 
the receptor was expressed on approximately 20–30% 
of both CD4+ and CD8+ T cells within blood. However, 
CXCR3+ T cells were relatively excluded from marrow 
where expression was seen on less than 5% of both 
populations.  A different pattern was observed within 
the patient group. Expression of CXCR3 on T cells 
was reduced to approximately 10% within the blood of 
the patient group and a similar level of expression was 
observed within bone marrow. As such, the pattern of 
distribution of CXCR3+ T cells between blood and 
marrow, which is normally much higher in blood, was 
reversed in the patient groups (Figure 4A, CD8+ T cells; 
Figure 4B, CD4+ T cells). 
The expression of CCR4 is markedly increased 
on CD8 and CD4 T cells within the bone marrow 
of patients with myeloma
CCR4 expression is observed on the majority of 
TH2 lymphocytes and we next analysed the frequency of 
CCR4+ expression on CD8+ and CD4+ T cells within the 
study groups. 
In control subjects there was a markedly higher 
expression of CCR4+ T-cells within the blood compared to 
the bone marrow (Figure 5A and 5B). Indeed, expression 
of this marker on T cells within marrow was low and 
represented a mean of 4.4% of the total population. 
In contrast the frequency of CCR4-expressing CD4+ 
T cells in BM was substantially increased in patients with 
myeloma to an average expression of 20% of the CD4+ 
Figure 1: Plasma cytokine levels (pg/ml) of CXCR3 related ligands were measured in bone marrow (BM) and blood in MM, 
MGUS and control patients by multiplex bead analysis (A) CXCL9 (B) CXCL10 (C) CXCL11. Data were analysed using a 
Kruskal Wallis where *** = p < 0.001, ** = p < 0.01, *p < 0.05.
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T cell pool (**p = < 0.01). This led to a clear and marked 
reversal of the normal distribution ratio of cells between 
blood and bone marrow (Figure 5B) indicating that 
paraproteinaemia is associated with relative accumulation 
of TH2 T cells within the bone marrow microenvironment.
Overall it can be seen that T cells which express 
CCR4 or CXCR3 are strongly excluded from bone 
marrow within healthy individuals, whereas in the patient 
group this pattern is lost and a relative equivalence 
between compartments is observed due to an increased 
proportion of cells within marrow and fewer cells retained 
with peripheral blood. 
The percentage of CD4+ Th17 cells is also 
increased within the bone marrow in patients 
with multiple myeloma
The potential importance of CD4+ TH17 cells in 
patients with multiple myeloma is an area of considerable 
interest and an increase in the frequency of such cells 
Figure 2: Plasma cytokine levels (pg/ml) of CCR4-related ligands were measured in bone marrow (BM) and blood in 
MM, MGUS and control patients by multiplex bead analysis. (A) CCL2 (B) CCL3 (C) CCL4 (D) CCL20. Data were analysed 
using a Kruskal Wallis where *** = p < 0.001, ** = P < 0.01, * = P < 0.05.
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within the bone marrow has been reported [10, 13, 24, 25]. 
Within the control group TH17 cells comprised 0.3% of the 
CD4+ T cell pool but were almost completely excluded 
from bone marrow (p = 0.0002). In contrast there was 
an 8 fold increase in the frequency of such cells in the 
marrow of patients with myeloma such that they expanded 
to represent 0.45% of the lymphoid pool (p = 0.0041) 
(Figure 6A). In view of the increased proportion of TH17 
cells within the bone marrow of the patient group we then 
went on to determine the potential role of CXCR3 and 
CCR4 in mediating this recruitment [37, 38]. CXCR3 
and CCR4 expression on TH17 cells was indeed reduced 
in the blood of the MM group but increased within MM 
bone marrow (Figure 6B and 6C for CXCR3 and CCR4 
respectively).
DISCUSSION
MGUS and myeloma are associated with the 
accumulation of malignant plasma cells within the bone 
marrow and as plasma cells and T cell subsets make 
numerous molecular interactions it is likely that the 
T cell response plays an important role in determining the 
natural history of the disease. This could act potentially 
to either support the growth of the malignant clone or to 
suppress plasma cell growth through tumour surveillance. 
Many alterations of the T cell repertoire in blood and 
bone marrow have been reported in patients with multiple 
myeloma. The physiological basis for these is poorly 
understood but it is possible that they represent potentially 
interesting opportunities for therapeutic intervention.
We studied the level of expression of inflammatory 
chemokines in the blood and bone marrow of patients 
with MGUS and MM and focussed on chemokines that 
are major determinants of the migration of the TH1 and 
TH2 T cell subsets, for which CXCR3 and CCR4 are 
characteristic and relatively specific markers. Elevated 
levels of several chemokines have previously been 
documented in MM and are thought to play a role in 
promoting MM proliferation and survival [27–29, 31, 
32, 34, 36, 39, 40]. The source of these chemokines 
appears to derive from both the myeloma plasma cells 
and associated stromal cells [34, 36, 40, 41]. As such, 
CXCL9 [42], CXCL12 [28] and CCL3 [43] have been 
shown to be produced by myeloma plasma cells whereas 
stromal cells have been shown to produce a range of 
chemokines, including CCL2, CCL7, CCL8 and CCL13 
from osteoclasts [44], CXCL8, CXCL11, CXCL12 and 
CCL2 from endothelial cells and bone marrow fibroblasts 
producing CXCL12 [28]. The CXCR 4/CXCR7/ (SDF) 
axis has been shown to be important in the recruitment 
of monocytic lineage cells and increased levels of 
CXCL12 are believed to promote the differentiation of M2 
macrophages [28, 30,27, 32]. 
Chemokine expression levels were very low in the 
normal bone marrow and indeed CCL2, CCL3, CXCL9 
and CXCL10 were completely undetectable. This is 
likely to reflect the role of marrow as both a primary and 
secondary lymphoid organ where homeostatic immune 
interactions predominate over inflammatory responses. 
A low but detectable level of several chemokines was 
observed within blood, which may reflect a degree 
Figure 3: Plasma cytokine levels (pg/ml) of CXCL8 (A) and CXCL12  (B) were measured in bone marrow (BM) and blood 
in MM, MGUS and control patients by multiplex bead analysis. Data were analysed using a Kruskal Wallis where *** = p < 0.001, 
** = P < 0.01, * = P < 0.05. 
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of systemic inflammation within peripheral tissue, 
or physiological establishment of a marrow-vascular 
chemotactic gradient. It it noteworthy that high CXCL9 
levels have recently been associated with poor clinical 
outcome in patients with myeloma [42].   
In contrast chemokine expression was substantially 
increased in the bone marrow of the patient group. The 
magnitude of this effect was considerable with the most 
marked effects seen for CCL4 (CCR4 ligand) and CXCL9 
(CXCR3 ligand), which were increased by 4 and 6 fold 
respectively in the bone marrow of patients with myeloma 
compared to controls. Li et al have also observed increased 
levels of CCL2 and CCL3 within the bone marrow of 
patients with myeloma but did not see an increased levels 
of CCL4 or CCL5 in their cohort [45]. These changes led 
to a marked reversal of the normal gradient of chemokine 
expression between blood and bone marrow in the patient 
groups. Specifically, whilst chemokine expression levels 
are normally higher in the vascular system, within the 
patient group they were either comparable between blood 
and marrow, or as in the case for CCL4, CCL20 and 
CXCL10, completely reversed such that chemokine levels 
were increased within marrow.
We next went on to investigate how these altered 
chemokine gradients might influence the distribution of 
major T cell subsets in patients with paraproteinaemia. TH1 
cells are characterised by expression of CXCR3 whilst 
the great majority of TH2 cells express CCR4, and we 
therefore took these as markers of the two major functional 
subsets of T cells within the lymphoid system [46]. Again 
the pattern of distribution within the control group was 
interesting in that the proportion of cells expressing the 
chemokine receptor was low within the bone marrow, 
typically less than 5% of the lymphoid pool. In contrast, 
a high percentage of T cells expressed these markers in 
peripheral blood in keeping with many previous reports. 
Figure 4: Percentage expression of CXCR3 on global CD8 T cells (A) and global CD4 T cells (B) in bone marrow (BM) and blood 
in MM, MGUS (blood only available) and control patients by flow cytometry. Data were analysed using a Kruskal Wallis where 
*** = p < 0.001, ** = p < 0.01, *p < 0.05. 
Figure 5: Percentage expression of CCR4 on global CD8 T cells (A) and global CD4 T cells (B) in bone marrow (BM) and blood in MM, 
MGUS (blood only available) and control patients by flow cytometry. Data were analysed using a Kruskal Wallis where *** = p < 0.001, 
** = p < 0.01, *p < 0.05. 
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The pattern of distribution of CXCR3+ and 
CCR4+ T cells was markedly altered in patients with 
paraproteinaemia and showed a characteristic pattern. In 
almost all cases the percentage of chemokine receptor-
positive cells was reduced in the blood and simultaneously 
increased in the bone marrow. Some of these alterations 
were striking with the proportion of bone marrow CD4 
and CD8+ T cells which expressed CCR4 being increased 
from 4.4% and 3% respectively in the control group to 
20% and 12% in patients with myeloma. A greater than 
two fold increase in CXCR3 expression on bone marrow T 
cells was also observed within the patient group. CXCR3 
and CCR4 can be expressed on both central memory and 
effector memory T cells and it will be of interest in future 
work to define both the differential trafficking of discrete 
CD8 T cell memory subsets and the relation of this to 
expression of major transcriptional regulators..
Negligible numbers of TH17 cells were detected 
within the bone marrow from control subjects but were 
markedly increased in the bone marrow of myeloma 
patients in keeping with previous studies [10, 13, 25]. 
However, this population still represented less than 1% of 
the total CD4+ T cell population. The relative frequency 
of TH17 cells in blood was not altered and a comparable 
recruitment of these cells to solid tumours has also been 
reported [23]. TH17 cells may play a particularly important 
role in the development of clinical complications of 
paraproteinaemia and have been linked to problems such 
as bone disease. TH17 cells can express a wide range of 
chemokine receptors [34, 35] and in our study we were 
able to examine the expression of CXCR3 and CCR4.  Our 
findings were very similar to those observed for the major 
CD4 and CD8 T cell subsets. 
Several studies have demonstrated alterations in 
T regulatory cells in marrow samples from patients with 
paraproteinaemia, although there remains considerable 
controversy [12]. We did not examine the T regulatory 
subset but as these cells often express CCR4 the pattern of 
chemokine expression that we observed could certainly act 
as a mechanism to mediate their recruitment. 
One limitation of our study is that we were not able 
to ascertain the absolute number of T cells within the 
different tissue compartments and so it is uncertain how 
proportional changes in T cell subsets reflect absolute 
changes in T cell distribution. Increased numbers of 
bone marrow T cells have been reported in MGUS and 
myeloma, and significant T cell infiltration is a common 
feature on diagnostic bone marrow aspirates and trephines 
[4]. In addition it should be noted that the increased 
proportion of T cells bearing chemokine receptors 
within marrow might potentially reflect increased local 
proliferation as well as preferential trafficking.
The relative importance of the individual chemokines 
and their ligands will need further investigation. It was 
noteworthy, however, that the frequency of CCR4+ T cells 
was substantially greater than the CXCR3+ population, 
suggesting that CCR4-binding chemokines may have a 
predominant influence on recruitment and retention of 
Figure 6: The frequency of CD4+ TH17 cells (A) was measured in both control individuals and MM and MGUS patients. The percentage 
expression of CXCR3 (B) and CCR4 (C) was then determined on the CD4+ TH17 cells within these compartments. Statistical analysis was 
by Kruskal Wallis where *** = p < 0.001, ** = p < 0.01, * p < 0.05 
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T cells to marrow in patients with myeloma. In addition we 
were not able to examine all of the chemokine receptors 
expressed by T cells and the level of their related chemokine 
ligands. Many of the chemokines that bind to CCR4 can also 
interact with additional chemokine receptors (e.g. CCR2, 
CCR5). Certainly we were able to observe that SDF-1, 
which binds to CXCR4, and CXCL8 (IL-8) which is a 
ligand for CXCR1/CXCR2, are also significantly elevated 
in myeloma. As such the role of the chemokine system in 
controlling the distribution of T cells within the lymphoid 
compartment in patients with myeloma is likely to be 
highly complex. Ponzetta et al have recently shown that 
administration of myeloma cells to immunodeficient mice 
leads to an increase in CXCL9 and CXCL10 within the 
murine bone marrow, supporting a direct role for tumour 
cells in the generation of inflammatory mediators [47]. In 
addition they also observed increased levels of CXCL10 
within the bone marrow of patients with multiple myeloma 
and this was correlated with a decrease in the number of 
CXCR3+ NK cells within blood. 
Our findings clearly indicate the presence of an 
‘inflammatory environment’ in the bone marrow of 
patients with multiple myeloma and we hypothesise 
that these chemokine gradients serve to drive T cell 
distribution as illustrated in Figure 7 although further work 
is needed to confirm this model. It will now be important 
to examine the relative roles of the neoplastic plasma 
cell and the tumour microenvironment in mediating this 
effect. These altered chemokine gradients may play a 
major role in the redistribution of T cell subsets in patients 
with paraproteinaemia. Importantly this effect occurs 
early in disease pathogenesis as it is clearly observed 
in the MGUS stage before the development of clinical 
complications. It is interesting to speculate on the potential 
clinical importance of the altered T cell subset distribution 
in relation to the clinical features of paraproteinemia. 
Increased susceptibility to infection is a major feature 
of this disorder and impairment of the adaptive immune 
response has been shown in several studies. In contrast, 
this may represent early evidence of a tumour-specific 
immune response and, indeed, only 1% of patients 
with MGUS progress to myeloma each year. A role for 
CXCL10 in the control of myeloma cell growth has indeed 
been observed [48]. However there is also considerable 
evidence that tumours induce an inflammatory response 
within their environment as a mechanism to support 
their survival and invasion. As such, anti-inflammatory 
drugs are being assessed for their potential therapeutic 
value in a range of diseases. Indeed, bone marrow levels 
of CCL3 and CCL20 have been shown to be higher in 
myeloma patients with increased levels of bone disease 
[49]. Recently Jak-2 inhibition with ruxolitinib and 
fedratinib have been shown to silence T helper cell 
cytokine production and reduce T regulatory cells [50]. 
Interventions that are able to suppress the elevated 
chemokine levels observed in patients with myeloma may 
therefore have potential beneficial effects and would be 
worthy of consideration as novel therapeutic agents [51].
Figure 7: The pattern of chemokine concentration and CXCR3+ and CCR4+ expression on T cell subsets within the 
blood and bone marrow in patients with paraproteinaemia.
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MATERIALS AND METHODS
Patients
Patients with MM and MGUS were recruited from 
specialist clinics at The Royal Wolverhampton Hospitals 
and Heart of England NHS Foundation Trusts. The study 
received approval from the Local Ethics Committees 
and informed written consent was obtained in all cases. 
Bone marrow aspirates (~1 ml) and peripheral blood 
(~5 mL) were obtained from patients at various stages of 
disease and mononuclear cells were purified by density 
centrifugation using Lymphoprep (Nycomed, Oslo, 
Norway). Plasma was collected after cell separation and 
snap frozen at –80°C. For studies of chemokine levels we 
obtained samples from 18 MM patients (12 at diagnosis, 3 
at relapse, 1 refractory disease and 2 post-treatment) and 
12 MGUS patients using paired bone marrow and blood 
samples. 
PBMC were available from 37 MM patients 
(22 at diagnosis, 4 at relapse, 2 in ‘plateau phase’ and 
9 asymptomatic patients) and 23 MGUS patients, and 
were used for examination of T cell subsets. Paired bone 
marrow and blood samples were also available from 
9 MM patients for comparative study of T cell profiles. 
10 patients undergoing thoracotomy surgery were recruited 
as a control group, from which bone marrow was available 
on 7 subjects. None of these patients had bone marrow 
disease or were undergoing treatment for significant 
medical conditions. A section of rib was obtained during 
surgery and the bone marrow flushed through using 
RPMI1640 with a needle and syringe. Mononuclear cells 
and plasma were harvested as above.
Luminex methodology
Multiplex bead analysis was performed on patient 
plasma samples using the Procarta Cytokine Assay Kit 
(Affymetrix, High Wycombe, UK) for a range of cytokines 
and chemokines including CXCL8 (IL-8), CXCL9 (MIG), 
CXCL10 (IP-10), CXCL11 (ITAC), CXCL12 (SDF-1), 
CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 
(RANTES) and CCL20 (MIP-3α). Measurements were 
performed as per manufacturer’s instructions. Briefly, 
plasma samples, diluted with an equal volume of PBS, 
were incubated with monoclonal antibody-coated capture 
beads for 1 hour at 20°C. Washed beads were further 
incubated with biotin-labelled polyclonal anti-human 
cytokine antibody for 30 minutes followed by streptavidin-
phycoerythrin for 30 minutes. Samples were analysed 
with a bioassay analyser (model 100; Luminex, Austin, 
USA). Standard curves of known concentrations of human 
antigen (Affymetrix, High Wycombe, UK) were used to 
convert fluorescence units to cytokine concentration 
(pg/ml). Results were calculated from standard curves 
prepared on each plate. 
Intracellular cytokine analysis
Mononuclear cells were stimulated with PMA and 
ionomycin for six hours in the presence of ‘Golgi stop’ 
(eBioscience, San Diego, CA) as described previously 
[33]. Briefly, cells were stained with surface antibodies 
CD8 Amcyan (BD Biosciences. Oxford, UK), CD3 
APC-Cy7 (Cambridge Biosciences, Cambridge, UK), 
CCR4 PE-Cy7 (BD Biosciences, Oxford, UK) and 
CXCR3 PE (BD Biosciences. Oxford, UK) for 20 mins 
at 4oC. Samples were washed, re-suspended in RPMI 
with 10% human serum (TCS Biosciences, Buckingham, 
UK) and then stimulated with PMA and ionomycin 
for six hours in the presence of ‘Golgi stop’. Cells 
were washed, stained with a dead cell exclusion dye 
(Invitrogen, Oregon, USA) at 4oC for 20 mins and then 
washed again before fixation with 2% paraformaldehyde 
at room temperature for 10–15 mins. After further 
washing, cells were permeabilised with 0.5% saponin for 
5 minutes followed by incubation with the intracellular 
antibodies IL-17A (BioLegend, London, UK) (2.5 ml), 
IFN-γ (BioLegend, London, UK) (0.5 ml) and isotype 
controls for 30 mins at room temperature. Samples were 
washed and analysed by flow cytometry using on LSR 
II flow cytometry. To define Th17 cells we measured the 
secretion of IL-17 using intracellular staining and FACS 
analysis. 
Statistical analysis
A Kruskal-Wallis test was used to assess the level 
of significance between plasma proteins produced by 
MM, MGUS and control patients. This was performed 
using Prism 5 for Windows (GraphPad, San Diego, 
CA). A Kruskal-Wallis test was also used to compare 
chemokine expression on T cells between peripheral 
blood and bone marrow mononuclear cells from MM, 
MGUS and aged-matched controls. Mann-Witney 
t-test was used to assess the level of significance of the 
percentage of CD4 IL-17 cells and CD4 T regulatory 
cells between peripheral blood and bone marrow 
mononuclear cells from MM, MGUS and aged-
matched controls and also to test the significance of 
CXCR3 and CCR4 expression on total CD4 and CD8 
T cells.
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